Sun Pharma Launches Fexuclue For Erosive Esophagitis In India

Sun Pharmaceutical Industries has launched Fexuprazan 40mg tablets in India under the brand name Fexuclue. The drug is approved for treating all grades of erosive esophagitis in adults.

Sun Pharma acquired rights for Fexuprazan from Korea-based Daewoong Pharmaceutical. The deal includes upfront, milestone, and royalty payments.

Fexuprazan, a potassium-competitive acid blocker, offers rapid action, works regardless of food intake, and has a long half-life of 9 hours—supporting better acid suppression and night-time symptom control.

A phase-3 study in India showed over 95% of patients achieved healing within 8 weeks. The drug was well tolerated, the company said in an exchange filing.